Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne

Study of an Investigational Vaccine for Mild Acne

Recruiting
18 years - 45 years
All
Phase 1/2
228 participants needed
4 Locations

Study Overview

The purpose of the VBE00009 study is to evaluate the safety, efficacy and immunogenicity of 2 administrations of the Acne mRNA vaccine candidate at single dose level in participants aged 18 to 45 years with mild acne. This study will consist of a Core Study followed by an optional Long-Term Extension (LTE). Core Study will include a Sentinel Cohort and a Main Cohort, with the Sentinel Cohort assessing the safety in a stepwise manner. If the participants consent to the LTE, they will be followed up for an additional 30 months after the last planned visit in the Core Study, to assess the long term effects of the vaccine.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acne
  • Age: 18 years - 45 years
  • Gender: All

Inclusion Criteria:

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests as judged by the investigator

  • Clinical diagnosis of mild facial acne vulgaris with:

    • IGA score of mild (grade 2 on the 5-grade IGA scale) AND
    • between 10 to 24 non-inflammatory lesions (ie, open and closed comedones) AND
    • between 5 to 19 inflammatory lesions (ie, papules and pustules) AND
    • no nodulocystic lesions (ie, nodules and cysts)

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within 6 months prior to the first study intervention administration; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known systemic hypersensitivity to any of the study intervention components; history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA coronavirus disease 2019 (COVID 19) vaccine
  • Previous history of or undergoing (suspected or confirmed) myocarditis and/or pericarditis and/or myopericarditis
  • Skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the study intervention or requires use of interfering topical, systemic, or surgical therapy
  • Excessive facial hair, facial tattoos, facial skin disorders, skin reactions that may interfere with the study assessments in the investigator's opinion (including - but not limited to - actinic keratosis, eczema, psoriasis, seborrheic dermatitis, rosacea, acute or recent sunburn) or skin infection
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

This study investigates mild acne. The purpose of this study is to evaluate the safety, efficacy, and immunogenicity of an investigational vaccine for individuals with mild acne.

The study focuses on assessing how safe and effective the investigational vaccine is, as well as how the body responds to it. The evaluation will include monitoring participants for any side effects and measuring the body's immune response to the vaccine.

  • Who can participate: Adults aged 18 to 45 with mild acne can participate if they are healthy and have a specific range of acne lesions.
  • Study details: Participants will receive two administrations of the investigational vaccine. Some participants may receive a placebo, which is an inactive substance that looks like the investigational vaccine but does not contain any medicine.
Updated on 08 Jul 2026. Study ID: NCT07013747

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language